David Calvet Canut։ Efdoralprin Alfa Shows Promise in Alpha 1 Antitrypsin Deficiency
David Calvet Canut, Chief Financial Officer at Rudder Marine Services and Ship Repairs S.L, shared a post on LinkedIn:
”A potential breakthrough for Alpha-1 Antitrypsin Deficiency (AATD) has emerged from Sanofi’s Phase 2 ElevAATe clinical trial.
The investigational treatment, efdoralprin alfa, has shown promising results for adults living with pulmonary emphysema caused by AATD.
Unlike current therapies that rely on donated plasma, efdoralprin alfa is a recombinant protein produced in the laboratory, designed to mimic the natural AAT protein that protects the lungs from inflammatory damage.
This could represent a significant advancement towards a more sustainable, supply-independent treatment option.
Key findings from the ElevAATe trial include:
- Patients achieved normal, stable levels of functional AAT protein, significantly higher than those seen with standard plasma-derived treatment.
- A greater proportion of days were spent at protective protein levels.
- The treatment was well tolerated, with a safety profile comparable to existing therapies.
- It is effective when administered every three to four weeks, potentially offering a more convenient treatment schedule.
Dr. Igor Barjaktarevic, lead investigator at UCLA, noted that achieving normal AAT levels without relying on plasma donations ‘would be a very positive change’ for patients living with Alpha-1.
Efdoralprin alfa has already received both Fast Track and Orphan Drug designations from the FDA, indicating the unmet need this treatment aims to address.
A long-term safety follow-up study (ElevAATe OLE) is now underway.”
Stay updated with Hemostasis Today.
-
Jun 10, 2026, 18:09Leonard Valentino: Innovation in Blood Disorders Being Catalyzed by Pathway to Cures
-
Jun 10, 2026, 18:00Smitirupa Mishra: Normal Hemoglobin Does Not Always Mean Normal Genes
-
Jun 10, 2026, 17:58Talat Uppal: Addressing HMB with RACGP’s Dr. Ramya Raman
-
Jun 10, 2026, 17:52Throw Back Thursday to Past Bruises Posted in the Glanzmann’s Research Foundation
-
Jun 10, 2026, 17:52Priya Prasad: In Massive Hemorrhage, Fibrinogen Is Often the First Clotting Factor to Fall
-
Jun 10, 2026, 17:51Mariam Swidan: Some Red Blood Cells Can’t Handle Pressure
-
Jun 10, 2026, 17:49Ankit Mathur: Hosting ISBT Academy Day on Rare Donor Program in India
-
Jun 10, 2026, 17:48Shadi Tabibian: When Patients Bleed but Standard Testing Is Normal
-
Jun 10, 2026, 17:47Mervyn Morgan: Discussing Current ITP Research at Imperial College London